Novo Nordisk (original) (raw)
Latest News for: Novo Nordisk
Novo Nordisk CEO: We are a cardiometabolic powerhouse
CNBC 09 Jun 2026
... what to expect from Novo’s pipeline and strategy in the years to come.
Novo Nordisk CEO: 'Common sense' should drive seniors on Medicare to opt for Wegovy
CNBC 09 Jun 2026
At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss the July 1 start date of GLP-1 coverage for seniors on Medicare ... .
Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before
CNBC 09 Jun 2026
At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss the launch of the Wegovy pill and how it became the best prescription drug launch in history ... .
Maziar Mike Doustdar, CEO at Novo Nordisk, Addresses the Webster Vienna Commencement Ceremony (Webster University)
Public Technologies 09 Jun 2026
) Maziar Mike Doustdar, CEO at Novo Nordisk, Addresses the Webster Vienna Commencement Ceremony ... He graduated from WVPU in 1994 with a BA in International Business and joined Novo Nordisk in 1992 as an office clerk in Vienna, Austria.
Novo Nordisk introduces updated Rybelsus® tablet formulation in Canada for adults living with type 2 diabetes
Canada Newswire 09 Jun 2026
MISSISSAUGA, ON, June 9, 2026 /CNW/ - Novo Nordisk today announced the Canadian availability of an updated formulation of Rybelsus® (semaglutide tablets), a prescription medicine used by adults with type 2 diabetes ... 1 Novo Nordisk Canada Inc.
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight ...
The Citizens 08 Jun 2026
CagriSema, a once-weekly investigational treatment that ...
Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch
Wall Street Journal 08 Jun 2026
The Danish drugmaker said the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, and reached a further two million prescriptions in the following 10 weeks ... .
Novo Nordisk A/S - share repurchase programme
Nasdaq Globe Newswire 08 Jun 2026
Bagsværd, Denmark, 8 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase ...
Novo Nordisk A/S – Share repurchase programme (Form 6-K) (Novo Nordisk A/S)
Public Technologies 08 Jun 2026
Novo Nordisk A/S - Share repurchase programme ... Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027 ... Novo Nordisk A/S.
Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions ...
The St Marys Daily Press 07 Jun 2026
Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic risk factors, and other obesity-related comorbidities1-6 ....
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
PR Newswire 07 Jun 2026
and BAGSVÆRD, Denmark, June 7, 2026 /PRNewswire/ -- Phase 3 results from Novo Nordisk's REIMAGINE 1-3 trials were presented today, showing significant reduction in HbA1c and weight in adults with type 2 diabetes (T2D) ... SOURCE NOVO NORDISK INC.
Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
PR Newswire 07 Jun 2026
"Novo Nordisk remains determined to continue playing a major part in addressing the global public health challenge of obesity by deeply understanding the needs of those who live with it ... Reference Novo Nordisk A/S ... SOURCE NOVO NORDISK INC.
Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in ...
The Essex Reporter 06 Jun 2026
A phase 2 study of investigational once-weekly subcutaneous ...
Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
PR Newswire 06 Jun 2026
... Novo Nordisk ... About Novo NordiskNovo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care ... Novo Nordisk Inc. Novo Nordisk A/S ... SOURCE NOVO NORDISK INC.